ImCheck

ImCheck Appoints Thomas Civik as Independent Chairman of the…

Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors Marseille, France, November 11, 2022 – ImCheck Therapeutics…